Google’s Gemma AI helped discover a drug combo that makes tumors immune-visible, marking a milestone for AI-driven biology.
Microrobots, small robotic systems that are less than 1 centimeter (cm) in size, could tackle some real-world tasks that cannot be completed by bigger robots. For instance, they could be used to monitor confined spaces and remote natural environments, to deliver drugs or to diagnose diseases or other medical conditions.
Researchers at Seoul National University recently introduced new modular and durable microrobots that can adapt to their surroundings, effectively navigating a range of environments. These tiny robots, introduced in a paper published in Advanced Materials, can be fabricated using 3D printing technology.
“Microrobots, with their insect-like size, are expected to make contributions in fields where conventional robots have struggled to operate,” Won Jun Song, first author of the paper, told Tech Xplore. “However, most microrobots developed to date have been highly specialized, tailored for very specific purposes, making them difficult to deploy across diverse environments and applications. Our goal was to present a new approach toward creating general-purpose microrobots.”
Identifying the neural mechanisms that support the regulation of vital physiological processes, such as drinking, eating and sleeping, is a long-standing goal within the neuroscience research community. As the disruption of these processes can severely impact people’s health and everyday functioning, uncovering their neural and biological underpinnings is of the utmost importance.
New insights gathered by neuroscientists could ultimately inform the development of more effective interventions designed to regulate vital physiological processes. Thirst and hunger are known to be regulated by homeostatic processes, biological processes that allow the body to maintain internal stability.
Yet drinking behavior can also be anticipatory, which means that animals and humans often adjust their actions (i.e., stop drinking) before the concentration of substances in the blood changes in response to drinking water. The mechanisms through which the brain predicts when it is the right time to stop drinking remain poorly understood.
ESA’s new Exploration Biobank received its first biological samples linked to European space research in Portugal this week.
The shipment contained over 1,400 human samples from the Vivaldi III bedrest and dry-immersion campaign that took place earlier this year at Medes space clinic in Toulouse, France. Vivaldi III had a group of volunteers lying down on a waterbed and another group in bedrest for 10 days to recreate some of the effects of spaceflight on the body.
Samples of blood, saliva, urine, stool and hair from the participants arrived at the Biobank of the Gulbenkian Institute for Molecular Medicine (GIMM) in Lisbon on 14 October following strict safety, traceability and conservation protocols.
After a decade of work, researchers are closer than ever to a key breakthrough in kidney organ transplants: being able to transfer kidneys from donors with different blood types than the recipients, which could significantly speed up waiting times and save lives.
A team from institutions across Canada and China has managed to create a ‘universal’ kidney, which can, in theory, be accepted by any patient.
Their test organ survived and functioned for several days in the body of a brain-dead recipient, whose family consented to the research.
Scientists have repaired a natural gateway into the brains of mice, allowing the clumps and tangles associated with Alzheimer’s disease to be swept away.
After just three drug injections, mice with certain genes that mimic Alzheimer’s showed a reversal of several key pathological features.
Within hours of the first injection, the animal brains showed a nearly 45 percent reduction in clumps of amyloid-beta plaques, a hallmark of Alzheimer’s disease.
A new breakthrough in a rare genetic disease which causes children to age rapidly has been discovered using ‘longevity genes’ found in people who live exceptionally long lives—over 100 years old. The research, by the University of Bristol and IRCCS MultiMedica, found these genes which help keep the heart and blood vessels healthy during aging could reverse the damage caused by this life-limiting disease.
This is the first study, published in Signal Transduction and Targeted Therapy, to show that a gene from long-lived people can slow down heart aging in a progeria model. Also known as Hutchinson-Gilford progeria syndrome (HGPS), progeria is a rare, fatal genetic condition of “rapid-aging” in children.
HGPS is caused by a mutation in the LMNA gene, which leads to the production of a toxic protein called progerin. Most affected individuals die in their teens due to heart problems, although a few, like Sammy Basso, the oldest known person with progeria, have lived longer. Sadly, late last year at the age of 28, Sammy passed away.